Clinical Trials
7 trialsNCT02194738 2026-05-29
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT01229150 2017-05-23
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00278187 2013-12-19
Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00072072 2013-09-20
Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00989690 2013-08-12
Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00955695 2013-08-02
Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00801385 2009-08-25
Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 2 Unknown